Avalo Therapeutics Discloses $98M Cash, Extending Runway into 2028

summarizeSummary

Avalo Therapeutics reported an estimated $98 million in cash and equivalents as of year-end 2025, projecting a cash runway into 2028.

check_boxKey Events

• Preliminary Cash Position

  The company estimates it held approximately $98 million in cash, cash equivalents, and short-term investments as of December 31, 2025.

• Extended Cash Runway

  This cash position is expected to provide a financial runway into 2028, significantly de-risking operations.

• Investor Presentation Update

  The financial estimates were disclosed in an updated investor presentation posted on the company's website.

auto_awesomeAnalysis

Avalo Therapeutics' disclosure of approximately $98 million in cash, cash equivalents, and short-term investments as of December 31, 2025, coupled with an expected cash runway into 2028, is a significant positive for the company. For a life sciences company, a prolonged cash runway substantially reduces near-term financing risk and provides stability to advance its clinical pipeline, particularly the ongoing Phase 2 LOTUS trial for AVTX-009. While the figures are preliminary and unaudited, this update signals strong financial health and operational capacity for the next two years, allowing management to focus on key development milestones without immediate capital concerns.